Skip to content
OpenCapital
Get started

LivaNova LIVN Neuromodulation — R&D

Other segment segments

Cardiopulmonary
$17.8M+47.7%

Similar metrics at other companies

Medtronic logo
MDTNeuroscience — Research and development expense
$139M-6.7%
Stryker logo
SYKMedSurg and Neurotechnology: — Research, development and engineering expenses
$231M+11.1%
Becton, Dickinson and Company logo
BDXMedical — Research and development expense
$130.75M+17.0%
Hinge Health, Inc. logo
HNGEReportable Segment — R&D
$25.54M+15.9%
Abbott logo
ABTMedical Devices — R&D
$444M+10.7%
Boston Scientific logo
BSXResearch and development expense
$516M+16.5%

Other financials

Income statement

See full
Revenue$362.3M+14.3%
Gross profit$243.7M+12.7%
Operating income$41.5M-14.7%
Net income$22.3M+107%
EPS (diluted)$0.40+107%

Balance sheet

See full
Cash & equivalents$539.7M-26.9%
Total debt$340.9M-49.7%
Total equity$1.2B+17.1%
Total assets$2.5B-1.7%

Cash flow

See full
Operating cash flow$15.2M-36.5%
CapEx$14.3M+32.4%
Free cash flow$926.0K-93.0%

Valuation

See full
Market cap$4.32B+62.8%

Profitability

See full
Gross margin67.5%-0.5pp
Operating margin13.4%+0.8pp
Net margin-16.1%-18.0pp
FCF margin11.2%-0.2pp

Returns & leverage

See full
Return on equity-17.6%-19.5pp
Debt / equity0.3×-0.4×
Current ratio1.3×-0.2×

Where this comes from

Reported directly by LivaNova in its filing.

Tagged under the XBRL concept us-gaap:ResearchAndDevelopmentExpense.

The official record: LivaNova’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about LivaNova's neuromodulation — r&d.

Connect your AI assistant and compare segments, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is LivaNova's neuromodulation — R&D?
LivaNova (LIVN) reported neuromodulation — R&D of $40.79M in Q1 2026.
How has LivaNova's neuromodulation — R&D changed year-over-year?
LivaNova's neuromodulation — R&D increased by 59.5% year-over-year, from $25.58M to $40.79M.
What is the long-term trend for LivaNova's neuromodulation — R&D?
Over 3 years (2022 to 2025), LivaNova's neuromodulation — R&D has grown at a 1.5% compound annual growth rate (CAGR), from $113.62M to $118.92M.
What does neuromodulation — R&D mean?
Represents expenditures dedicated to the innovation, clinical trials, and development of new neuromodulation technologies and product enhancements. This is a critical indicator of the segment's long-term competitive positioning and future growth pipeline.